Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Camelia Radulescu is active.

Publication


Featured researches published by Camelia Radulescu.


Lancet Oncology | 2015

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies

Brian I. Rini; Audrey Goddard; Dejan Knezevic; Tara Maddala; Ming Zhou; Hakan Aydin; Steven C. Campbell; Paul Elson; Serge Koscielny; Margarita Lopatin; Christer Svedman; Jean Francois Martini; J. Andrew Williams; Virginie Verkarre; Camelia Radulescu; Yann Neuzillet; Isabelle Hemmerle; Marc Olivier Timsit; Athanasios C. Tsiatis; Michael Bonham; Thierry Lebret; Arnaud Mejean; Bernard Escudier

BACKGROUND The likelihood of tumour recurrence after nephrectomy in localised clear cell renal cell carcinoma is well characterised by clinical and pathological parameters. However, these assessments can be improved and personalised by the addition of molecular characteristics of each patients tumour. We aimed to develop and validate a prognostic multigene signature to improve prediction of recurrence risk in clear cell renal cell carcinoma. METHODS In the development stage, we investigated the association between expression of 732 genes, measured by reverse-transcription PCR, and clinical outcome in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a nephrectomy at the Cleveland Clinic (OH, USA). 516 genes were associated with recurrence-free interval. 11 of these genes were selected by further statistical analyses, and were combined with five reference genes (ie, 16 genes in total), from which a recurrence score algorithm was developed. The recurrence score was then validated in an independent cohort of 626 patients from France with stage I-III clear cell renal cell carcinoma who had also undergone nephrectomy. The association between the recurrence score and the risk of recurrence and cancer-specific survival in the first 5 years after surgery was assessed using Cox proportional hazard regression, stratified by tumour stage (stage I vs stage II vs III). FINDINGS In our primary univariate analysis, the continuous recurrence score (median 37, IQR 31-45) was significantly associated with recurrence-free interval (hazard ratio 3·91 [95% CI 2·63-5·79] for a 25-unit increase in score, p<0·0001). In multivariable analyses, the recurrence score was significantly associated with the risk of tumour recurrence (hazard ratio per 25-unit increase in the score 3·37 [95% CI 2·23-5·08], p<0·0001) after stratification by stage and adjustment for tumour size, grade, or Leibovich score. The recurrence score was able to identify a clinically significant number of both high-risk stage I and low-risk stage II-III patients. A heterogeneity study on separate samples showed little to no intratumoural variability among the 16 genes. INTERPRETATION Our findings validate the recurrence score as a predictor of clinical outcome in patients with stage I-III clear cell renal cell carcinoma, providing a more accurate and individualised risk assessment beyond existing clinical and pathological parameters. FUNDING Genomic Health Inc and Pfizer Inc.


Cancer Research | 2017

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma

Clémence Granier; C. Dariane; Pierre Combe; Virginie Verkarre; Saïk Urien; Cécile Badoual; Hélène Roussel; Marion Mandavit; Patrice Ravel; Mathilde Sibony; Lucie Biard; Camelia Radulescu; Emeline Vinatier; Nadine Benhamouda; Michaël Peyromaure; S. Oudard; Arnaud Mejean; Marc Olivier Timsit; Alain Gey; Eric Tartour

Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+ T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8+ T cells coexpressing PD-1 and Tim-3 correlated with an aggressive phenotype and a larger tumor size at diagnosis. Coexpression of PD-1 and Tim-3 above the median conferred a higher risk of relapse and a poorer 36-month overall survival. Notably, other CD8+T-cell subsets did not exert a similar effect on overall survival. Moreover, only the PD-1+Tim-3+ subset of CD8+ T cells exhibited impaired function after stimulation. Our findings establish intratumoral Tim-3+PD1+CD8+ T cells as critical mediators of an aggressive phenotype in RCC. Use of the Vectra tool may be useful to identify similarly critical prognostic and predictive biomarkers in other tumor types and their response to immunotherapy. Cancer Res; 77(5); 1075-82. ©2016 AACR.


Urologic Oncology-seminars and Original Investigations | 2014

Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non–muscle-invasive bladder cancer with positive results on urine cytology

Yann Neuzillet; Charlotte Methorst; Marc P. Schneider; Thierry Lebret; Mathieu Rouanne; Camelia Radulescu; Vincent Molinié; Jean-François Dreyfus; Veronique Pelcat; Henry Botto

OBJECTIVE In accordance with the European Association of Urology guidelines, a second transurethral resection of the bladder (TURB) is recommended for high-grade or T1-category tumors. This practice brings into question the benefit of photodynamic diagnosis (PDD) in reducing the residual disease after TURB in patients with positive results on urine cytology showing high-grade cancer cells. METHODS AND MATERIALS A prospective, bicentric, randomized study comparing white light cystoscopy (WLC)+PDD with hexaminolevulinate arm with WLC alone (control arm) during the first TURB in patients with primary non-muscle-invasive bladder cancer and with positive results on urine cytology showing high-grade cancer cells. Patients underwent a first TURB with WLC and PDD or WLC alone, and then a second TURB with WLC and PDD, after 4 to 6 weeks. The number of tumors visualized in WLC and PDD and histology of the TURB specimen was recorded to perform a statistical analysis comparing both the 2 arms. RESULTS A total of 151 patients were enrolled (hexaminolevulinate, n = 72; control, n = 79). The number of visualized tumors did not increase with PDD in the first or second TURB. During the second TURB, the residual tumor rate was not reduced in patients who had PDD during the first TURB. No significant difference was observed regarding the pattern of category and grade, the size, and the recurrence and progression risks during either the first or the second TURB. CONCLUSIONS In the setting of primary non-muscle-invasive bladder cancer with positive results on urine cytology, performing a second TURB allows to diagnose residual tumor in approximately half of the cases. This rate was not significantly reduced by the use of the PDD during the first TURB.


Hormone Molecular Biology and Clinical Investigation | 2015

Obesity and hypogonadism are associated with an increased risk of predominant Gleason 4 pattern on radical prostatectomy specimen

Yann Neuzillet; Jean-Pierre Raynaud; Thierry Lebret; Audrey Pichon; Camelia Radulescu; Vincent Molinié; Henry Botto

Abstract Purpose: To compare histological features of prostate cancer according to both obesity, defined by a body mass index (BMI) ≥30 kg/m2, and androgenic status in patients who underwent radical prostatectomy. Materials and methods: Between March 2007 and September 2013, clinical, pathological and biological data were prospectively collected for patients referred for radical prostatectomy in a single European center. Preoperative total testosterone (TT) and bioavailable testosterone (bioT) serum determinations were performed. The threshold for hypogonadism was set at TT <3 ng/mL. The preoperative PSA value was registered. Gleason score (GS) and predominant Gleason pattern (PrdGP) were determined in prostate tissue specimens, and crosschecked by two uro-pathologists. Statistical analyzes were done for PrdGP4 risk assessment. Results: A total of 937 consecutive patients were included. One hundred and thirty-five filled the criterion for obesity (14.4%), out of which 42 had TT <3 ng/mL (31.1%), while in non-obese patients, only 97 had TT <3 ng/mL (12.0%). In prostate specimens, mean GS was 6.8±0.5: 291 patients (31.1%) had a PrdGP4. The incidence of PrdGP4 was higher (p<0.001) in the 135 obese patients [50% when hypogonadal (p<0.02) or 42% when eugonadal (p<0.005)] than in non-obese patients (28.9% and 27.1%, respectively). In multivariable analyzis for PrdGP4 risk, obesity, TT <3 ng/mL, PSA, and age were independent risk factors. Conclusions: Both obesity and hypogonadism are independent risk factors for PrdGP4 in patients who underwent radical prostatectomy and should be taken into account in localized prostate cancer management, to improve the therapeutic choice, especially when prostate sparing approach is considered.


Urologia Internationalis | 2017

Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score

Hakim Slaoui; Yann Neuzillet; Tarek Ghoneim; Mathieu Rouanne; Abdelali Abdou; Pierre Marie Lugagne-Delpon; Antoine Scherrer; Camelia Radulescu; Christian Delancourt; Vincent Molinié; Thierry Lebret

Background: We aim to correlate multiparametric magnetic resonance imaging (mpMRI) of the prostate reporting (Prostate Imaging Reporting and Data System [PI-RADS] version 2) with the Gleason score into both radical prostatectomy (RP) specimen and MRI fusion-targeted biopsies (FTB). Methods: mpMRI of 74 patients who underwent an RP after FTB were retrospectively reviewed. The Gleason score distribution was compared according to the PI-RADS score using the Kruskal-Wallis test. Results were compared to those of the mpMRI-guided biopsy of the same anatomical zone. For comparison, 903 RP specimen and their corresponding classical biopsies were also reviewed. Cohens kappa concordance test was used to compare biopsies and prostatectomy specimen analyses. Results: An exact match between Gleason grade in RP specimen and FTB was found in 62% of the cases. There was no significant difference in Gleason score ≤7 (3 + 4) vs. ≥7 (4 + 3) distribution according to the PI-RADS scores (p = 0.096). Overall, Kappa coefficients were similar with MRI-targeted biopsies compared to classical biopsies (κ = 0.378, 95% CI [0.194-0.563], and κ = 0.316, 95% CI [0.259-0.374], respectively). Conclusions: PI-RADS score was not associated with significant differences regarding Gleason score distribution within target. Moreover, concordance of Gleason score in both MRI-targeted and classical biopsies with those within target in RP specimen was weak.


PLOS ONE | 2018

From arterial stiffness to kidney graft microvasculature: Mortality and graft survival within a cohort of 220 kidney transplant recipients

Lynda Cheddani; Camelia Radulescu; Michel Chaignon; Alexandre Karras; Yann Neuzillet; Jean-Paul Duong; Nahid Tabibzadeh; Emmanuel Letavernier; Michel Delahousse; Jean-Philippe Haymann

Background Aortic stiffness assessed by carotid-femoral pulse wave velocity (CF-PWV) is a predictor of mortality in several populations. However, little is known in kidney transplant recipients. Our objectives were to evaluate the ability of CF-PWV measured 3 months following transplantation to predict mortality, graft loss and its potential links to measured Glomerular Filtration Rate (mGFR) or kidney graft microvasculature parameters. Methods The study is based on a monocentric retrospective cohort including 220 adult kidney graft recipients evaluated three months after transplantation. CF-PWV measures, clinical, laboratory and histological data performed at 3 (M3) and 12 months (M12) following transplantation were retrospectively collected. The two primary endpoints were all-cause mortality and occurrence of end stage renal disease (ESRD) defined by initiation of dialysis. Results After a median follow up of 5.5 years [1.9; 8.8], death and graft loss occurred in 10 and 12 patients respectively. M3 CF-PWV was an independent mortality risk factor (HR = 1.29 [1.03; 1.61]; p = 0.03), despite no aortic stiffness variation during the first year of transplantation. Of notice, M3 CF-PWV was not associated with M12 mGFR or ESRD outcome. Graft microcirculation assessed by Banff vascular fibrous intimal thickening score (cv) worsened between M3 and M12 (p = 0.01), but no link was found with CF-PWV, mGFR or ESRD outcome. Surprisingly, acute rejections at M3 were associated after adjustment with mortality (p = 0.03) but not ESRD. Conclusion Aortic stiffness measured 3 months after kidney transplantation is a strong predictor of mortality with no obvious influence on kidney graft microvasculature or graft loss.


M S-medecine Sciences | 2018

Tim-3 - Biomarqueur et cible thérapeutique en cancérologie

Clémence Granier; Alain Gey; C. Dariane; Arnaud Mejean; Marc-Olivier Timsit; Charlotte Blanc; Virginie Verkarre; Camelia Radulescu; E. Fabre; Yann Vano; S. Oudard; Cécile Badoual; Eric Tartour

T cells harboring multiple co-inhibitory molecules lose their anti-tumoral functionality. PD-1 is a clinically approved target in cancer therapy, but its expression alone does not mean dysfunctionality. The expression of Tim-3 on numerous cell types (T cell, Treg, dendritic cell, myeloid cells) favors tumor escape to immune cells. Within many tumors, PD-1/Tim-3 coexpressing CD8-T cells lose their ability to secrete cytokines (IFNγ, IL-2, TNFα) and their intratumoral infiltration correlates with a bad prognosis. Tim-3 recently appeared as a potential biomarker of anti-PD-1 resistance. Combined blockade of PD-1 and Tim-3 axis demonstrated potent clinical efficacy in preclinical models and reinforced the rationale of using an anti-Tim-3 to override tumor resistance.


The Journal of Urology | 2013

1485 DIAGNOSTIC PERFORMANCE OF PROSTATE BIOPSY FOR DETERMINING THE PREDOMINANCE OF GLEASON GRADE 4

Yann Neuzillet; Jean-Pierre Raynaud; Vincent Molinié; Camelia Radulescu; Thierry Lebret; Henry Botto

INTRODUCTION AND OBJECTIVES: Predominance of Gleason grade 4 is a prognostic factor of the first order in prostate cancer. The objective of this study was to evaluate the performance of the prostate biopsy (PB) to determine the predominance of Gleason grade 4. METHODS: From March 2007 to September 2012, 786 patients had a PB before a radical prostatectomy in the same center. Gleason score determined by the PB was compared to that established in the analysis of the prostatectomy specimen. RESULTS: With PB, the Gleason score was over-assessed, properly assessed, or underestimated in 9.4%, 48.4% and 42.2% of cases respectively. The sensitivity and specificity of the PB to determine the predominance of Gleason grade 4, were 43.7% and 94.6% respectively. The positive predictive value and negative predictive value were 78.7% and 78.8% respectively. The risk of not diagnosing the predominance of Gleason grade 4 was 56.3%. CONCLUSIONS: The Gleason score was determined accurately by the PB in only one case out of two. More over the risk of being unawared of Gleason grade 4 predominant was estimated at 56.3%. Thus the overall risk of underestimation of Gleason score should be known and taken into account in treatment option.


World Journal of Urology | 2015

Positive surgical margins after radical prostatectomy: What should we care about?

Caroline Pettenati; Yann Neuzillet; Camelia Radulescu; Jean-Marie Hervé; Vincent Molinié; Thierry Lebret


Journal of Clinical Oncology | 2014

Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC).

Bernard Escudier; Serge Koscielny; Margarita Lopatin; Christer Svedman; Virginie Verkarre; Camelia Radulescu; Yann Neuzillet; Isabelle Hemmerle; Marc Olivier Timsit; Athanasios C. Tsiatis; Michael Bonham; Dejan Knezevic; Thierry Lebret; Audrey Goddard; Mejean Arnaud

Collaboration


Dive into the Camelia Radulescu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Henry Botto

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Virginie Verkarre

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Arnaud Mejean

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge